论文部分内容阅读
目的:研究中药“808”联合拉米夫定治疗活动性肝炎肝硬变的临床疗效。方法:随机选择ALC 62例,用分层随机抽样法随机平均分为治疗组和对照组。治疗组:温补肾阳、清热解毒、活血化瘀中药,1帖/3日加拉米夫定0.1/日;对照组:拉米夫定0.1g/日加退黄、保肝及对症治疗。疗程6～18 mo。结果:治疗组血清HBVDNA阴转率90.32％(28/31),和对照组相比,差异显著(P<0.01);两组治疗后,血清生化总胆红素、谷丙转氨酶、球蛋白明显下降,白蛋白明显升高,两组相比,差异显著(P<0.01);B超门静脉宽度变窄,两组相比,差异显著(P<0.05);临床存活率:治疗组为93.75％,对照组为74.19％,两组相比,差异显著(P<0.01)。结论:中药“808’’联合拉米呋啶治疗ALC,能抑制病毒复制,改善肝脏循环和肝功能,提高ALC的存活率。
Objective: To study the clinical efficacy of traditional Chinese medicine “808” combined with lamivudine in the treatment of active cirrhosis. Methods: 62 cases of ALC were randomly selected and randomly divided into treatment group and control group by stratified random sampling method. Treatment group: Warming Kidney Yang, detoxification, promoting blood circulation and removing blood stasis medicine, 1 post / 3 plus lamivudine 0.1 / day; control group: lamivudine 0.1g / day plus yellow, liver and symptomatic treatment. Course of treatment 6 ~ 18 months. Results: The negative rate of serum HBVDNA in the treatment group was 90.32% (28/31), which was significantly different from the control group (P <0.01). After treatment, the levels of serum total bilirubin, alanine aminotransferase and globulin were significantly higher (P <0.01). The width of the portal vein of B was narrowed, the difference was significant (P <0.05). The clinical survival rate was 93.75% in the treatment group , While the control group was 74.19%. There was significant difference between the two groups (P <0.01). Conclusion: Chinese medicine “808” combined with lamivudine in treatment of ALC can inhibit virus replication, improve liver circulation and liver function, and improve the survival rate of ALC.